Metformin-Induced Eosinophilic Interstitial Lung Disease.

Metformin, a mainstay treatment for type two diabetes mellitus has several side effects, ranging from mild to life-threatening ones. One report has found the combination of metformin/glibenclamide a culprit for interstitial lung disease. Other studies have shown that metformin has a protective effect on the lungs. We report a rare case of a 64-year-old male who presented with progressive dyspnea while he was on metformin alone. He was diagnosed with eosinophilic interstitial lung disease (ILD). This was confirmed by a pulmonary function test (PFT), high-resolution chest computed tomography scan (HRCT), and bronchoscopy with bronchoalveolar lavage (BAL). Known causes for eosinophilic pneumonia were excluded, and the patient's condition improved significantly after withdrawing metformin. We report this case due to the rarity of the condition. In fact, this is the only case in the literature, of metformin as the sole agent causing eosinophilic pneumonitis.

Genetics of cholesterol efflux.

Plasma levels of high-density lipoprotein cholesterol (HDL-C) show an inverse association with coronary heart disease (CHD). As a biological trait, HDL-C is strongly genetically determined, with a heritability index ranging from 40 % to 60 %. HDL represents an appealing therapeutic target due to its beneficial pleiotropic effects in preventing CHD. This review focuses on the genetic basis of cellular cholesterol efflux, the rate-limiting step in HDL biogenesis. There are several monogenic disorders (e.g., Tangier disease, caused by mutations within ABCA1) affecting HDL biogenesis. Importantly, many disorders of cellular cholesterol homeostasis cause a reduced HDL-C. We integrate information from family studies and linkage analyses with that derived from genome-wide association studies (GWAS) and review the recent identification of micro-RNAs (miRNA) involved in cellular cholesterol metabolism. The identification of genomic pathways related to HDL may help pave the way for novel therapeutic approaches to promote cellular cholesterol efflux as a therapeutic modality to prevent atherosclerosis.

Relation between ABO blood groups and obesity in a Saudi Arabian population.

OBJECTIVES: ABO blood groups have been shown to be associated with different diseases. Very few studies have attempted to detect the association of ABO blood groups with obesity. The goal of this study is to find any potential relation between ABO blood groups and high body mass index (BMI) among a Saudi population, which may contribute to underlying genetic disorders. METHODS: A cross-sectional descriptive study was conducted using a structured questionnaire that contained general demographic data, including weight, height, type of ABO blood group and the participants' opinion, to determine the association between the ABO blood groups and obesity. RESULTS: Our study included 1171 participants, including 596 (50.9%) women. A plurality of participants' ages (47%) was between 15 and 25 years. The prevalence of obesity was 35.7% in men and 20.3% in women, while the prevalence of overweight was 30% in men and 25.3% in women. Blood group O was reported to be the most common blood group (46%), followed by blood group A (31.4%), while blood groups B and AB were found in 16.1% and 6.5% of participants, respectively. The prevalence of obesity (BMI ≥ 30) among participants based on blood group O, A, B, and AB was 13.7%, 9%, 4.8%, and 2.2%, respectively. There was no statistically significant difference between the prevalence of obesity or high BMI and ABO blood groups. CONCLUSION: Overall, our study did not show a significant relation between overweight and obesity and ABO blood groups. However, the elevation of the prevalence of overweight and obesity, mainly among the younger generations of the Saudi population, requires more awareness and educational programs.